Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$25.44 - $35.16 $1.21 Million - $1.67 Million
47,500 Added 21.11%
272,500 $8.29 Million
Q4 2021

Feb 14, 2022

SELL
$15.6 - $35.4 $3 Million - $6.81 Million
-192,409 Reduced 46.1%
225,000 $7.03 Million
Q2 2021

Aug 16, 2021

BUY
$16.81 - $20.0 $82,520 - $98,180
4,909 Added 1.19%
417,409 $7.77 Million
Q1 2021

May 17, 2021

BUY
$13.65 - $21.31 $4.54 Million - $7.09 Million
332,500 Added 415.63%
412,500 $7.38 Million
Q4 2020

Feb 16, 2021

SELL
$9.49 - $16.04 $2.09 Million - $3.53 Million
-220,000 Reduced 73.33%
80,000 $1.23 Million
Q3 2020

Nov 16, 2020

SELL
$10.82 - $13.35 $2.35 Million - $2.9 Million
-217,500 Reduced 42.03%
300,000 $3.32 Million
Q2 2020

Aug 14, 2020

SELL
$10.21 - $14.9 $1.13 Million - $1.65 Million
-111,000 Reduced 17.66%
517,500 $6.49 Million
Q1 2020

May 15, 2020

SELL
$8.08 - $17.57 $2.34 Million - $5.08 Million
-289,000 Reduced 31.5%
628,500 $7.13 Million
Q4 2019

Feb 14, 2020

BUY
$8.11 - $14.65 $1.74 Million - $3.15 Million
215,000 Added 30.6%
917,500 $12 Million
Q3 2019

Nov 14, 2019

BUY
$8.74 - $10.51 $8,740 - $10,510
1,000 Added 0.14%
702,500 $6.33 Million
Q2 2019

Aug 14, 2019

BUY
$8.51 - $10.75 $1.27 Million - $1.6 Million
149,000 Added 26.97%
701,500 $6.92 Million
Q1 2019

May 14, 2019

BUY
$6.39 - $10.42 $95,850 - $156,300
15,000 Added 2.79%
552,500 $5.61 Million
Q4 2018

Feb 14, 2019

BUY
$5.61 - $12.62 $308,550 - $694,100
55,000 Added 11.4%
537,500 $3.39 Million
Q3 2018

Nov 07, 2018

BUY
$9.0 - $14.9 $292,500 - $484,250
32,500 Added 7.22%
482,500 $6.37 Million
Q2 2018

Aug 15, 2018

BUY
$4.8 - $9.2 $2.16 Million - $4.14 Million
450,000 New
450,000 $4.14 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.